USFDAOct 29, 2026, 06:11 AM
HUTCHMED: Sovleplenib Gets US FDA Orphan Drug Designation for ITP
AI Summary
HUTCHMED announced that the US FDA has granted Orphan Drug Designation to its drug candidate, sovleplenib, for the treatment of primary immune thrombocytopenia (ITP). This designation offers potential benefits including 7 years of US market exclusivity upon approval and eligibility for development incentives. Sovleplenib is an oral Syk inhibitor. The company also noted that New Drug Applications for sovleplenib in ITP and another condition are currently under regulatory review by China's NMPA.
Key Highlights
- HUTCHMED announces sovleplenib granted US FDA Orphan Drug Designation for primary immune thrombocytopenia (ITP).
- Orphan Drug Designation provides eligibility for 7 years of US market exclusivity upon regulatory approval.
- Sovleplenib is a novel, selective, oral spleen tyrosine kinase (Syk) inhibitor.
- ITP is an autoimmune disorder affecting fewer than 200,000 people in the US.
- New Drug Applications for sovleplenib in ITP and warm antibody autoimmune hemolytic anemia are under NMPA review in China.
Price Impact
More from HCM